Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update

Patel, Priya; Robinson, Paula D.; Baggott, Christina; Gibson, Paul; Ljungman, Gustaf; Massey, N.J.A.; Ottaviani, Giulia; Phillips, Bob; Revon‐Rivière, Gabriel; Treister, Nathaniel S.; White, Marie; Cabral, Sandra; Dupuis, L. Lee; Sung, Lillian

doi:10.1016/j.ejca.2021.05.013

Cited by 39 publications

(32 citation statements)

References 26 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study settings ranged from case series, cohort studies, and non-randomized trials to RCTs. The results are promising as demonstrated in the meta-analysis by Patel et al in 2021 (97). They showed that PBM could significantly reduce the incidence of severe OM in pediatric patients based on 16 studies.…”

Section: Acute Oral Mucositismentioning

confidence: 92%

“…They showed that PBM could significantly reduce the incidence of severe OM in pediatric patients based on 16 studies. However, due to significant differences in PBM protocols in these trials (as IN the MASCC/ISOO analysis), it is hard to make definite recommendations for pediatric patients at the moment (97)(98)(99)(100). Nonetheless, these studies emphasize the non-invasive, patient-friendly, safe and well-tolerated therapy PBM represents.…”

Section: Acute Oral Mucositismentioning

confidence: 99%

See 1 more Smart Citation

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

Self Cite

View full text Add to dashboard Cite

DisclaimerThis article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols.ObjectiveThis position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).BackgroundThere is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care.MethodsA literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed.ResultsThere is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors.ConclusionsThere is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.

show abstract

Section: Acute Oral Mucositismentioning

confidence: 92%

Section: Acute Oral Mucositismentioning

confidence: 99%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent application of NHSN criteria in pediatric hospitals in the United States demonstrated that MBI accounted for 40% of CLABSI in immunocompromised pediatric patients, which replicates the findings in our study ( 11 ). While strategies to decrease mucositis, such as oral rinses, cryotherapy, and low level light therapy have been recommended in high resource settings, this will not prevent all MBI ( 12 ). Moreover, the feasibility of implementation and the cost vs. benefit of interventions will have to be evaluated within the local context.…”

Section: Discussionmentioning

confidence: 99%

High morbidity and mortality associated with primary bloodstream infections among pediatric patients with cancer at a Guatemalan tertiary referral hospital

Mukkada

Melgar

Bullington

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Infectious complications remain major contributors to adverse outcomes in patients treated for non-communicable disease, particularly in resource limited settings. We performed a 5-year retrospective study of primary bloodstream infections at a dedicated pediatric oncology center in Guatemala. Two hundred and twelve episodes occurring in 194 unique patients qualified for inclusion. Patients required intensive care unit admission in 55% of episodes and death occurred in 24% of episodes. Despite subspecialty support in infectious diseases, poor outcomes, including prolonged hospitalization and mortality, were frequent. Our findings suggest that investments in laboratory and clinical data collection are critical to understanding the contributors to poor outcomes and therefore to improving the quality of bloodstream infection management in resource limited settings.

show abstract

“…8 Nevertheless, cryotherapy was previously indicated to be performed only on older and cooperative pediatric patients. 9 Honey has attracted the attention of medical care in the past decades because of its tissue healing, antibacterial and antioxidant properties, 10 and has been shown to be an acceptable traditional medicine (Natural Product) globally. 11 Based on the present knowledge, honey is efficiently used to treat chemotherapy-induced OM.…”

Section: Introductionmentioning

confidence: 99%

Use of Honey in the Management of Chemotherapy-Associated Oral Mucositis in Paediatric Patients

Yin¹,

Simons²,

Francisco³

et al. 2022

CMAR

View full text Add to dashboard Cite

Background: Oral mucositis (OM) is a critical condition during chemotherapy in both adult and child cancer patients. Paediatric cancer patients have a higher prevalence of OM than adult cancer patients. Honey is a natural product that has been reported to have the best tissue healing properties. The present mini-review focused on the evaluation of the effectiveness of oral care with honey products in the treatment and prophylaxis of chemotherapy-induced OM in child patients. Methods: A network of electronic English databases including CINAHL, CENTRAL, EMBASE, MEDLINE and PubMed, were used for primary search from April 2010 to April 2020. We have also considered data collected from ClinicalTrials.gov, Web of Science and Google Scholar. PRISMA software was used to build collective data. Controlled trials were included in this review and were critically appraised by Down and Black. The narrative synthesis was performed. Results: A total number of 346 data of children and adolescents with cancer were considered in this short review. All patients were from three randomized controlled trial articles and two were non-randomised controlled trial articles. Based on the evidence so far revealed, honey may show an effect in the treatment and prophylaxis of OM. The analysis of collected data revealed that the probability value P<0.05. The honey enhanced recovery time and severity of OM were significantly compared with those without honey treatment receiving group of pediatric patients. Conclusion: Honey not only has been shown to have the capability for healing injured tissues but it is also a more economical treatment, and it has fewer side effects compared to synthetic drugs. Honey or honey products can prevent chemotherapy-induced OM (CIOM) and be the best treatment to grade I, II and III CIOM. However, it is disappointing that studies involving children as patients were few, and limited data available so far.

show abstract

Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update

Cited by 39 publications

References 26 publications

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

High morbidity and mortality associated with primary bloodstream infections among pediatric patients with cancer at a Guatemalan tertiary referral hospital

Use of Honey in the Management of Chemotherapy-Associated Oral Mucositis in Paediatric Patients

Contact Info

Product

Resources

About